… AZD1222 (ChAdOx1 nCoV-19) vaccine in preventing coronavirus disease 2019 (Covid-19) …
Accordingly, AZD1222 is being distributed for vaccination in more than 100 countries across …

… doses of the ChAdOx1 nCoV-19 vaccine, administered 21 to 35 … Covid-19, a history of
anaphylaxis in relation to vaccination, and … The ChAdOx1 nCoV-19 vaccine was developed at the …

… vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a
meningococcal conjugate vaccine (… -2 infection or of COVID-19-like symptoms were randomly …

… patients with Covid-19. As of March 20, 2021, when administration of the vaccine was paused,
… the first dose of the ChAdOx1 nCoV-19 vaccine and none had received the second dose. …

… against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with …
COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine …

… or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19. We used a
… had blood samples referred for investigation of vaccine-associated thrombotic events, with …

… antibodies were detected in all mice vaccinated with ChAdOx1 nCoV-19, whereas no
neutralization was detected in serum from mice vaccinated with ChAdOx1 GFP (Fig. 1b). Splenic T …

… Immunogenicity of vaccines is often worse in older adults as a … vaccine, ChAdOx1 nCoV-19
(AZD1222), in young adults, and now describe the safety and immunogenicity of this vaccine …

… syndrome coronavirus … COVID-19 vaccine administration. Here we describe a case of ADEM
presenting 2 weeks after receiving the first dose of ChAdOx1 nCoV-19, a COVID-19 vaccine …

… vaccine benefits still outweigh its side effects (SEs). Therefore, this study aims to provide early
independent evidence on the vaccine … received the AstraZeneca COVID-19 vaccine. The …